Sungha Park Selected Research

4- (2- (4- hydroxybenzyl)- phenoxy)- N- methylbutylamine

1/2021	Insights on home blood pressure monitoring in Asia: Expert perspectives from 10 countries/regions.
1/2020	Current status of ambulatory blood pressure monitoring in Asian countries: A report from the HOPE Asia Network.
1/2020	2020 Consensus summary on the management of hypertension in Asia from the HOPE Asia Network.
1/2020	Diversity of and initiatives for hypertension management in Asia-Why we need the HOPE Asia Network.
1/2020	Asian management of hypertension: Current status, home blood pressure, and specific concerns in Korea.
1/2019	2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension.
1/2018	Guidance on home blood pressure monitoring: A statement of the HOPE Asia Network.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sungha Park Research Topics

Disease

49	Hypertension (High Blood Pressure) 01/2022 - 04/2005
24	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 06/2008
22	Inflammation (Inflammations) 01/2021 - 02/2007
19	Coronary Artery Disease (Coronary Atherosclerosis) 01/2018 - 06/2004
17	Atherosclerosis 01/2022 - 06/2004
14	Myocardial Infarction 01/2021 - 06/2004
12	Heart Failure 11/2021 - 06/2005
10	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2020 - 05/2008
8	Atherosclerotic Plaque (Atheroma) 12/2021 - 01/2011
8	Insulin Resistance 01/2018 - 07/2006
7	Diabetes Mellitus 01/2018 - 09/2007
6	Stroke (Strokes) 01/2022 - 11/2016
6	Thrombosis (Thrombus) 11/2021 - 07/2003
5	Hyperplasia 01/2022 - 02/2007
5	Dyslipidemias (Dyslipidemia) 09/2021 - 09/2007
4	Hyperaldosteronism (Conn Syndrome) 01/2022 - 06/2007
4	Neoplasms (Cancer) 01/2022 - 09/2013
4	Essential Hypertension 10/2021 - 11/2012
4	Carotid Artery Diseases 05/2019 - 03/2008
4	Fibrosis (Cirrhosis) 01/2017 - 03/2012
4	Chronic Kidney Failure (Chronic Renal Failure) 01/2017 - 10/2009
3	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 08/2013
3	Hypotension (Low Blood Pressure) 11/2021 - 01/2020
3	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 09/2021 - 08/2018
3	Vascular Calcification 02/2021 - 01/2012
3	Vascular Diseases (Vascular Disease) 01/2021 - 10/2010
3	Chronic Renal Insufficiency 01/2021 - 12/2017
3	Cardiotoxicity 01/2020 - 06/2013
3	Hypercholesterolemia 12/2019 - 07/2005
3	Hypertrophy 04/2019 - 03/2008
3	Hemorrhage 01/2019 - 06/2008
3	Prehypertension 01/2019 - 08/2008
3	Type 2 Diabetes Mellitus (MODY) 01/2019 - 05/2008
3	Atrial Fibrillation 01/2019 - 11/2016
3	Flushing 11/2010 - 04/2005
3	Pathologic Constriction (Stenosis) 08/2004 - 07/2003
2	Dementia (Dementias) 01/2022 - 01/2020
2	Coronary Disease (Coronary Heart Disease) 01/2022 - 08/2007
2	Adenoma (Adenomas) 01/2022 - 12/2016
2	Albuminuria 01/2021 - 04/2008
2	Sepsis (Septicemia) 01/2020 - 11/2012
2	Dizziness (Lightheadedness) 01/2020 - 11/2019
2	Masked Hypertension 01/2020 - 01/2020

Drug/Important Bio-Agent (IBA)

22	Antihypertensive Agents (Antihypertensives)IBA 01/2022 - 04/2005
13	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2011
11	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021 - 07/2005
11	Receptor for Advanced Glycation End ProductsIBA 11/2019 - 02/2007
10	CholesterolIBA 01/2022 - 07/2005
10	Proteins (Proteins, Gene)FDA Link 04/2019 - 05/2008
8	LipidsIBA 01/2021 - 06/2007
8	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 07/2006
7	Angiotensin IIIBA 01/2022 - 07/2006
7	CalciumIBA 02/2021 - 11/2013
7	4- (2- (4- hydroxybenzyl)- phenoxy)- N- methylbutylamineIBA 01/2021 - 01/2018
7	C-Reactive ProteinIBA 08/2017 - 06/2007
6	DiureticsIBA 01/2022 - 07/2019
6	CreatinineIBA 01/2022 - 08/2017
6	AldosteroneIBA 01/2022 - 06/2007
6	omega-Chloroacetophenone (Mace)IBA 01/2021 - 06/2008
6	HDL CholesterolIBA 01/2018 - 07/2005
6	AdiponectinIBA 08/2013 - 05/2008
5	fimasartanIBA 10/2021 - 10/2016
5	LDL CholesterolIBA 01/2021 - 07/2005
5	SaltsIBA 01/2021 - 08/2011
5	LigandsIBA 01/2017 - 01/2011
4	ReninIBA 01/2022 - 06/2007
4	Angiotensin Receptor AntagonistsIBA 02/2021 - 01/2019
4	Atorvastatin (Lipitor)FDA Link 01/2020 - 03/2012
4	Triglycerides (Triacylglycerol)IBA 01/2018 - 07/2005
4	CytokinesIBA 01/2016 - 01/2009
4	Insulin (Novolin)FDA Link 01/2015 - 07/2006
3	AlbuminsIBA 01/2022 - 12/2017
3	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2021 - 08/2015
3	oxidized low density lipoproteinIBA 01/2021 - 03/2012
3	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020 - 06/2013
3	Rosuvastatin Calcium (Crestor)FDA Link 01/2020 - 10/2016
3	SodiumIBA 01/2020 - 08/2011
3	Ezetimibe (Zetia)FDA Link 12/2019 - 03/2012
3	Pharmaceutical PreparationsIBA 07/2019 - 04/2005
3	Phenobarbital (Luminal)FDA Link 01/2017 - 07/2003
3	ChemokinesIBA 01/2017 - 07/2007
3	Amlodipine (Norvasc)FDA LinkGeneric 10/2016 - 04/2005
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2016 - 03/2012
2	Enalapril FDA LinkGeneric 11/2021 - 01/2020
2	sacubitril and valsartan sodium hydrate drug combinationIBA 11/2021 - 01/2020
2	Perindopril FDA LinkGeneric 10/2021 - 07/2019
2	Biological ProductsIBA 06/2021 - 03/2016
2	SolutionsIBA 05/2021 - 01/2017
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 02/2021 - 01/2021
2	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 02/2021 - 01/2020
2	Retinaldehyde (Retinal)IBA 01/2021 - 10/2020
2	SurvivinIBA 01/2020 - 01/2015

Therapy/Procedure

16	Therapeutics 01/2021 - 02/2005
9	Stents 10/2009 - 07/2003
5	Patient Readmission 11/2021 - 03/2010
5	Percutaneous Coronary Intervention 01/2014 - 11/2005
4	Ligation 01/2018 - 01/2009
3	Drug Therapy (Chemotherapy) 02/2021 - 01/2019
3	Peritoneal Dialysis 12/2016 - 01/2012
3	Catheters 09/2016 - 07/2006